Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

NCT01474551 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual

Conditions

Melanoma

Interventions

DRUG: vemurafenib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]